<div id="readability-page-1"><p>Shares of Kezar Life Sciences, Inc. (NASDAQ:KZR - Get Free Report) have earned a consensus rating of &#34;Reduce&#34; from the six analysts that are presently  covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation and four have issued  a hold recommendation on  the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $6.00.</p><div><p><span></span><span>Get <strong>Kezar Life Sciences</strong> alerts:</span></p></div><h2>Kezar Life Sciences Stock Performance</h2><p>Shares of NASDAQ KZR opened at $7.39 on Tuesday. The company has a market cap of $54.46 million, a P/E ratio of -0.96 and a beta of 0.40. Kezar Life Sciences has a 52-week low of $3.53 and a 52-week high of $7.55. The firm's fifty day moving average is $7.06 and its two-hundred day moving average is $6.49. </p><p>Kezar Life Sciences (NASDAQ:KZR - Get Free Report) last released its quarterly earnings data on Friday, March 27th. The company reported ($1.99) EPS for the quarter, missing the consensus estimate of ($1.39) by ($0.60).  As a group, analysts forecast that  Kezar Life Sciences will post -2.24 EPS for the current fiscal year. </p><h2>Hedge Funds Weigh In On Kezar Life Sciences</h2><p>Institutional investors have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC bought a new stake in  Kezar Life Sciences in the 4th quarter worth approximately $1,741,000.  Affinity Asset Advisors LLC bought a new position in shares of  Kezar Life Sciences during the 4th quarter valued at approximately $1,441,000.  BML Capital Management LLC boosted its position in shares of  Kezar Life Sciences by 13.5% during the 3rd quarter. BML Capital Management LLC now owns 720,787 shares of the company's stock valued at $2,811,000 after acquiring an additional 85,604 shares during the last quarter.  Aldebaran Capital LLC purchased a new position in shares of  Kezar Life Sciences in the fourth quarter valued at $507,000.  Finally, Credit Industriel ET Commercial purchased a new position in shares of  Kezar Life Sciences in the first quarter valued at $398,000. Hedge funds and other institutional investors own  67.90% of the company's stock. </p><h2>About Kezar Life Sciences</h2> (Get Free Report)<p>Kezar Life Sciences is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapies that modulate the innate immune system. The company's research centers on selective inhibition of the immunoproteasome, a key protein complex involved in antigen processing and secretion of inflammatory cytokines. By targeting this pathway, Kezar aims to address unmet medical needs in autoimmune and inflammatory diseases with high specificity and a favorable safety profile.  </p><p>The company's lead development candidate, KZR-616, is a selective immunoproteasome inhibitor being evaluated in multiple clinical trials for autoimmune conditions such as systemic lupus erythematosus, lupus nephritis, polymyositis and dermatomyositis.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Kezar Life Sciences</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1pS?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1pS"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Kezar Life Sciences Right Now?</h2><p>Before you consider Kezar Life Sciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kezar Life Sciences wasn't on the list.</p><p>While Kezar Life Sciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ARKG

<p>Kezar Life Sciences, Inc. (NASDAQ:KZR) has received a consensus rating of "Reduce" from six analysts, with two recommending a sell and four a hold. The average one-year price target is $6.00. The stock opened at $7.39, with a market cap of $54.46 million. The company reported a quarterly EPS of ($1.99), missing estimates. Institutional investors hold 67.90% of the stock. Kezar focuses on developing therapies for autoimmune diseases, with its lead candidate KZR-616 in clinical trials.</p>

Market Beat

Kezar Life Sciences

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

VanEck Biotech ETF

iShares Biotechnology ETF

iShares US Pharma

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

VG Health

iShares Global Healthcare

Health Care Select Sector SPDR

Kezar Life Sciences, Inc. (NASDAQ:KZR) Given Consensus Recommendation of "Reduce" by Analysts